^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
Soltamox (tamoxifen citrate)
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Jazz
Drug class:
Estrogen receptor modulator
Related drugs:
7d
TALES: Fertility Preservation Using Tamoxifen and Letrozole in Estrogen Sensitive Tumors Trial (clinicaltrials.gov)
P3, N=309, Recruiting, University of California, San Francisco | Trial completion date: Mar 2026 --> Mar 2028 | Trial primary completion date: Mar 2026 --> Mar 2028
Trial completion date • Trial primary completion date
|
letrozole • Soltamox (tamoxifen citrate)
28d
MCN_Tam: Chemoprevention With Tamoxifen in Pre-Invasive Pancreas Mucinous Cystic Neoplasms Not Undergoing Immediate Resection (clinicaltrials.gov)
P1, N=15, Recruiting, University of Nebraska | Trial completion date: May 2027 --> May 2029 | Trial primary completion date: Nov 2026 --> Nov 2028
Trial completion date • Trial primary completion date
|
Soltamox (tamoxifen citrate)
1m
ETHAN - ET for Male BC (clinicaltrials.gov)
P2, N=60, Recruiting, Jose Pablo Leone | Trial primary completion date: Apr 2026 --> Apr 2027
Trial primary completion date
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
|
ER positive • HR positive • HER-2 negative • HR positive + HER-2 negative • HER-2 negative + ER positive
|
Verzenio (abemaciclib) • anastrozole • Firmagon (degarelix) • Soltamox (tamoxifen citrate)
2ms
PIKALO-1: First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors (clinicaltrials.gov)
P1/2, N=880, Recruiting, Eli Lilly and Company | N=178 --> 880
Enrollment change • First-in-human
|
PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha)
|
PIK3CA mutation
|
Ibrance (palbociclib) • Verzenio (abemaciclib) • Kisqali (ribociclib) • fulvestrant • letrozole • anastrozole • exemestane • metformin • Inluriyo (imlunestrant) • tersolisib (LY4064809) • Soltamox (tamoxifen citrate)
3ms
A011203: Tamoxifen Citrate or Z-Endoxifen Hydrochloride in Treating Patients With Locally Advanced or Metastatic, Estrogen Receptor-Positive, HER2-Negative Breast Cancer (clinicaltrials.gov)
P2, N=81, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Feb 2026 --> Feb 2027
Trial completion date
|
ER (Estrogen receptor)
|
ER positive • HER-2 negative • ER positive + HER-2 negative • HER-2 negative + ER positive
|
Zonalta (Z-endoxifen hydrochloride) • Soltamox (tamoxifen citrate)
3ms
Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer (clinicaltrials.gov)
P3, N=5018, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Oct 2032 --> Jan 2027
Trial completion date
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
|
HER-2 negative
|
Oncotype DX Breast Recurrence Score®Test
|
letrozole • anastrozole • exemestane • Soltamox (tamoxifen citrate)
4ms
Assessing the Efficacy and Safety of Anti-HER2 Therapy in Nigerian Women With HER2+ Breast Cancer Before and After Surgery (clinicaltrials.gov)
P2, N=74, Recruiting, University of Chicago | Not yet recruiting --> Recruiting
Enrollment open
|
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 positive
|
docetaxel • Perjeta (pertuzumab) • Kadcyla (ado-trastuzumab emtansine) • letrozole • goserelin acetate • Soltamox (tamoxifen citrate)
4ms
Study of Infigratinib in Combination With Tamoxifen in Hormone Receptor Positive, HER2 Negative, FGFR Altered Advanced Breast Cancer (clinicaltrials.gov)
P1, N=4, Terminated, Jennifer Lee Caswell-Jin | Phase classification: P1b --> P1
Phase classification
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
|
ER positive • HER-2 negative • PGR positive • HER-2 negative + AR positive + ER positive • HER-2 negative + ER positive
|
Truseltiq (infigratinib) • Soltamox (tamoxifen citrate)
5ms
Umbrella Trial of Subtype-Targeted Therapies in ER+/HER2- Breast Cancer (clinicaltrials.gov)
P2, N=19, Completed, Jennifer Lee Caswell-Jin | Suspended --> Completed
Trial completion
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
|
ER positive • HER-2 negative • HER-2 negative + ER positive
|
Piqray (alpelisib) • fulvestrant • zotatifin (eFT226) • Soltamox (tamoxifen citrate)
7ms
Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer (clinicaltrials.gov)
P2/3, N=260, Completed, National Cancer Institute (NCI) | Active, not recruiting --> Completed
Trial completion
|
BRAF (B-raf proto-oncogene)
|
Mekinist (trametinib) • paclitaxel • letrozole • pegylated liposomal doxorubicin • topotecan • Myocet (non-pegylated liposomal doxorubicin) • Duomeisu (pegylated liposomal doxorubicin) • Soltamox (tamoxifen citrate)
11ms
Umbrella Trial of Subtype-Targeted Therapies in ER+/HER2- Breast Cancer (clinicaltrials.gov)
P2, N=19, Suspended, Stanford University | Active, not recruiting --> Suspended
Trial suspension
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
|
ER positive • HER-2 negative • HER-2 negative + ER positive
|
Piqray (alpelisib) • fulvestrant • zotatifin (eFT226) • Soltamox (tamoxifen citrate)
1year
TALES: Fertility Preservation Using Tamoxifen and Letrozole in Estrogen Sensitive Tumors Trial (clinicaltrials.gov)
P3, N=309, Recruiting, University of California, San Francisco | N=144 --> 309 | Trial completion date: Jan 2025 --> Mar 2026 | Trial primary completion date: Jan 2025 --> Mar 2026
Enrollment change • Trial completion date • Trial primary completion date
|
letrozole • Soltamox (tamoxifen citrate)
Share via
